Impact Factor 3.161 | CiteScore 3.13
More on impact ›

Clinical Trial ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Psychiatry | doi: 10.3389/fpsyt.2019.00656

Paliperidone Extended-Release Tablets for The Treatment of Methamphetamine Use Disorder in Chinese Patients after acute treatment:A randomized, double-blind, placebo-controlled exploratory study

 GANG WANG1, Li Ma1, Xuebing Liu1, Xue Yang1, Sheng Zhang1, Yongde Yang1, Zaifeng Xu1 and Wei Hao2*
  • 1Wuhan Mental Health Center, China
  • 2Mental Health Institute of the Second Xiangya Hospital, Central South Universit y, China

Background: To test paliperidone extended-release (ER) for efficacy in decreasing methamphetamine (METH) use and reducing psychotic symptoms in METH-dependent patients after detoxification. Rates of adverse events with paliperidone ER versus placebo were also compared. Methods: After discharge and seven days without medication, 80 treatment-seeking METH-dependent participants were randomly assigned to paliperidone ER (3 mg once daily; n=40) or placebo (once daily; n=40) for 84 days under double-blind conditions. The participants attended clinics weekly to provide urine samples that were analyzed for METH metabolites, to complete research assessments, and to receive substance use and medication counseling. Results: Fifty-six percent of follow-up visits and final visits were completed. The placebo group had a significantly lower retention (51.5 days, 95% CI, 41.6-61.4) than the paliperidone ER group (69.4 days, 95% CI, 61.9-76.9, p=0.016). Paliperidone ER was a protective factor against psychotic symptom relapse (hazard ratio (HR)=0.15, p=0.003). Moreover, there were statistically significant effects of paliperidone ER on psychosis severity and METH craving, assessed by mean changes in Positive and Negative Syndrome Scale (PANSS) total scores, Clinical Global Impression-Severity (CGI-S) scores and METH craving scores over time (p=0.006, p=0.002 and p=0.03 for the medication by time interaction effect, respectively). There were no statistically significant differences between the two groups on METH use. There were no serious adverse events related to the study drug. Conclusion: Compared with placebo, paliperidone ER administration resulted in a better retention rate and lower psychotic symptom relapse, but we did not find significantly reduced METH use among adults after acute METH detoxification treatment.

Keywords: Methamphetamine, Paliperidone extended-release (ER) tablet, psychosis, exploratory study, efficacy, Safety

Received: 03 Jun 2019; Accepted: 14 Aug 2019.

Copyright: © 2019 WANG, Ma, Liu, Yang, Zhang, Yang, Xu and Hao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Prof. Wei Hao, Mental Health Institute of the Second Xiangya Hospital, Central South Universit y, Changsha, Hunan Province, China, weihao57@csu.edu.cn